Last reviewed · How we verify

Ultracet® — Competitive Intelligence Brief

Ultracet® (Ultracet®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain Management.

marketed Opioid analgesic combination Mu-opioid receptor; norepinephrine and serotonin transporters; COX enzymes Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ultracet® (Ultracet®) — Labopharm Inc.. Ultracet combines tramadol (an opioid agonist and monoamine reuptake inhibitor) with acetaminophen to provide enhanced pain relief through dual analgesic pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ultracet® TARGET Ultracet® Labopharm Inc. marketed Opioid analgesic combination Mu-opioid receptor; norepinephrine and serotonin transporters; COX enzymes
Ultracet Tablets Ultracet Tablets Pfizer marketed Opioid analgesic combination Mu-opioid receptor; norepinephrine and serotonin transporters; COX enzymes
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
oxycodone/APAP oxycodone/APAP Albert Einstein College of Medicine marketed Opioid analgesic combination Opioid receptors (mu, delta, kappa); cyclooxygenase enzymes
hydroxycontin/acetominophen hydroxycontin/acetominophen University of Rochester marketed Opioid analgesic combination Mu-opioid receptor; cyclooxygenase (COX)
bucain + fentanyl bucain + fentanyl University of Debrecen marketed Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
lidocaine and sufentanil lidocaine and sufentanil RenJi Hospital marketed Local anesthetic and opioid analgesic combination Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

  1. VA Office of Research and Development · 3 drugs in this class
  2. Rothman Institute Orthopaedics · 2 drugs in this class
  3. Labopharm Inc. · 2 drugs in this class
  4. University of Rochester · 2 drugs in this class
  5. Montefiore Medical Center · 2 drugs in this class
  6. Maastricht University Medical Center · 2 drugs in this class
  7. Henry Ford Health System · 1 drug in this class
  8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Albert Einstein College of Medicine · 1 drug in this class
  10. Johnson & Johnson Taiwan Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ultracet® — Competitive Intelligence Brief. https://druglandscape.com/ci/ultracet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: